ZSNI-21

ZSNI-21 (48 h) potently inhibits proliferation of Bel-7402, HCC-LM3, RBE, MCF-7, and A549 cancer cells with IC₅₀ values ranging from 2.399 μM to 5.789 μM, while exhibiting low toxicity to HL-7702 and HEK 293 T normal cells^[1].
ZSNI-21 functions as a dual inhibitor of ADAM17 and HDAC2 with IC₅₀ values of 0.939 μM and 0.844 μM respectively, while also potently inhibiting HDAC6 (IC₅₀ = 0.106 μM) and moderately inhibiting HDAC1 (IC₅₀ = 1.270 μM)^[1].
ZSNI-21 (6 h) exhibits strong intracellular binding affinity for ADAM17, HDAC1, HDAC2, and HDAC6 in Bel-7402 cells^[1].
ZSNI-21 (1.5-12 μM; 48 h) reduces Notch intracellular domain (NICD) levels, increases acetylated histone H3 and H4 levels, modulates apoptosis-related proteins, and decreases Cyclin D1 expression in Bel-7402 cells^[1].
ZSNI-21 (3-12 μM; 24 h) inhibits long-term proliferation and colony formation of Bel-7402 cells in a concentration-dependent manner^[1].
ZSNI-21 (1.5-12 μM; 48 h) induces apoptosis in Bel-7402 cells in a concentration-dependent manner, as evidenced by apoptotic nuclear morphology and increased total apoptosis proportion (up to 40.2%)^[1].
ZSNI-21 (1.5-6 μM; 48 h) inhibits migration of HCC-LM3 cells and reduces expression of EMT-related proteins in a concentration-dependent manner^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.